Stoney!!!!!!!!!!!!!! I quit. These are often bottoms // I have been there brother-- the next one always fires! XSPA! HEY ROBIN HOOD: GUMMYBEARADVISORS SAYS XSPA IS A BUY
Hey. Weird symptoms. If you look on the internet you get Covid-everything but my kid has some weird symptoms and I'm worried about that post Covid stuff the kids get even though his test was negative. Could all of the Covid have been out of his system. By his elbows on both arms large break out rash scary. On one finger these bumps.. all of this is on the net with Covid but so is everything...
I wish my Mom was alive. This could be bad news for me or not-- Walgreens Boots Alliance up 4% to $46.29 after Sky says exploring Boots sale 13:26 WBA I mean you sell the co you keep your rental obligations right....
Oh wait... Walgreens exploring options for British retail chain Boots, Sky reports 13:23 WBA That's fine-
Anti-Cathie Wood SARK ETF soars 6% Friday and over 30% on the month Dec. 03, 2021 1:42 PM ETCollaborative Investment Series Trust - Tuttle Capital Short Innovation ETF (SARK), ARKK Tuttle Capital Short Innovation ETF (NASDAQ:SARK), which trades inversely to the popular ARK Innovation ETF (NYSEARCA:ARKK), has soared Friday as the ETF is +6.1%. Conversely, ARKK is -6.1%. The newly launched SARK has only been available for trading since Nov. 9 and has since surged +30.8% as Cathie Wood's flagship fund has struggled -25.1% over the same period. Moreover, in the 17 available trading days, the two exchange traded funds have experienced a 55.9% performance differential. Below is a chart of the two funds since SARK's launch: From a head-to-head fund flows viewpoint, ARKK is a powerhouse ETF with $17.5B assets under management, but since SARK's launch, the fund has only taken in $35.8M in new money, which is only $7.6M more than SARK's $28.2M according to etfdb.com.
Cathie Wood’s Ark snaps up over two million Ginkgo Bioworks shares Dec. 03, 2021 11:47 AM ETGinkgo Bioworks Holdings, Inc. (DNA)ARKG, ARKK A selloff that followed a scathing report from a short seller has not discouraged Ark Investment Management, run by the notable fund manager Cathie Wood, to load up more shares of Ginkgo Bioworks (DNA -17.0%). Early October, Ginkgo (NYSE:DNA) shares crashed after Scorpion Capital called the company a "colossal scam." The stock has lost more than a tenth of its value since then, as shown in the graph below. However, Ark’s ARK Genomic Revolution Multi-Sector ETF (ARKG -4.6%) and ARK Innovation ETF (ARKK -6.2%) have bought ~782.3K and ~1.3M Ginkgo (DNA) shares on Thursday, according to 24/7 Wall St. Both ETFs are trading lower in morning hours. The short report led to an informal inquiry by the U.S. Department of Justice, Ginkgo (DNA) disclosed in its Q3 2021 earnings release last month.